Literature DB >> 24132509

Phylogenetic analysis of HCV-4d in Turkey: the curious case of Kayseri province.

Massimo Ciccozzi1, Gianguglielmo Zehender, Ceylan Polat, Alessia Lai, Tuba Kayman, Chiara Sorrentino, Erika Ebranati, Eleonora Cella, Alessandra Lo Presti, Hakan Abacioglu.   

Abstract

In Turkey, genotype 1, especially type 1b virus, causes approximately 90% of these infections, while types 2, 3, and 4 exist, albeit in low prevalences and are due to relatively recent and limited introductions. Two recent reports from Kayseri, a relatively large city in Central Anatolia, indicated unusually high prevalence for type 4 infections in the province reaching a 35% among patients admitted to hospitals for treatment of chronic hepatitis C. In this study, the origin, the demographic history, and the dynamic of the epidemic of unusual HCV genotype 4d in Turkey by using Bayesian coalescent-based method were investigated. A gene flow migration approach was also used to describe the synchronous geographical dispersal and genetic diversification of this unusual genotype in Kayseri province. The Turkish clade had a tMRCA of 44 years corresponding to the year 1967 and seems to have a different origin being completely segregated from the European one. Gene flow migration analysis indicated that Kayseri province appeared to be the epicenter of HCV-4d epidemic, exporting the infections. The demographic history of HCV-4d showed that the epidemic started in 1970s year then following a slow exponential growth until 1980s. The Turkish monophyletic clade suggests a segregate circulation of the epidemic in this region mostly due to unsafe parenteral medical procedures (with drug addiction playing a relatively negligible role).
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  HCV 4d; Turkey; phylogeny

Mesh:

Year:  2013        PMID: 24132509     DOI: 10.1002/jmv.23787

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

Review 1.  Enigmatic origin of hepatitis B virus: an ancient travelling companion or a recent encounter?

Authors:  Gianguglielmo Zehender; Erika Ebranati; Elena Gabanelli; Chiara Sorrentino; Alessandra Lo Presti; Elisabetta Tanzi; Massimo Ciccozzi; Massimo Galli
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

2.  Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.

Authors:  Bilgehan Aygen; Neşe Demirtürk; Orhan Yıldız; Mustafa Kemal Çelen; İlhami Çelik; Şener Barut; Onur Ural; Ayşe Batırel; Reşit Mıstık; Funda Şimşek; Ali Asan; Gülden Ersöz; Nesrin Türker; Hüseyin Bilgin; Sami Kınıklı; Faruk Karakeçili; Gökmen Zararsız; The Study Group For Viral Hepatitis Of The Turkish Society Of Clinical Microbiology And Infectious Diseases
Journal:  Turk J Gastroenterol       Date:  2020-04       Impact factor: 1.852

3.  Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi's sarcoma and non-Kaposi's cases.

Authors:  Paola Cordiali-Fei; Elisabetta Trento; Marta Giovanetti; Alessandra Lo Presti; Alessandra Latini; Massimo Giuliani; Giovanna D'Agosto; Valentina Bordignon; Eleonora Cella; Francesca Farchi; Carmela Ferraro; Ilaria Lesnoni La Parola; Carlo Cota; Isabella Sperduti; Antonella Vento; Antonio Cristaudo; Massimo Ciccozzi; Fabrizio Ensoli
Journal:  J Exp Clin Cancer Res       Date:  2015-01-16

4.  The epidemic dynamics of hepatitis C virus subtypes 4a and 4d in Saudi Arabia.

Authors:  Ahmed A Al-Qahtani; Guy Baele; Nisreen Khalaf; Marc A Suchard; Mashael R Al-Anazi; Ayman A Abdo; Faisal M Sanai; Hamad I Al-Ashgar; Mohammed Q Khan; Mohammed N Al-Ahdal; Philippe Lemey; Bram Vrancken
Journal:  Sci Rep       Date:  2017-03-21       Impact factor: 4.379

5.  Evaluation of the Abbott Real Time HCV genotype II assay for Hepatitis C virus genotyping.

Authors:  Fatma Mutlu Sariguzel; Elife Berk; Selma Gokahmetoglu; Baris Derya Ercal; Ilhami Celik
Journal:  Pak J Med Sci       Date:  2015 Sep-Oct       Impact factor: 1.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.